Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
760 results about "Cell migration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cell migration is a central process in the development and maintenance of multicellular organisms. Tissue formation during embryonic development, wound healing and immune responses all require the orchestrated movement of cells in particular directions to specific locations. Cells often migrate in response to specific external signals, including chemical signals and mechanical signals. Errors during this process have serious consequences, including intellectual disability, vascular disease, tumor formation and metastasis. An understanding of the mechanism by which cells migrate may lead to the development of novel therapeutic strategies for controlling, for example, invasive tumour cells. The cells are complex and have organelles.
Resorbable polymeric device for localized drug delivery
InactiveUS20050177118A1Good adhesionMinimizes procedural discomfortMedical devicesMammal material medical ingredientsOsteoblastHigh doses
An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. Another embodiment is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.
Owner:KENSEY NASH CORP
Device for regeneration of articular cartilage and other tissue
InactiveUS20050074481A1Good adhesionMinimizes procedural discomfortBone implantMammal material medical ingredientsSubchondral boneOsteoblast
An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.
Owner:KENSEY NASH CORP
Anti-integrin immunoconjugates, methods and uses
The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
Owner:IMMUNOGEN INC +1
Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams
ActiveUS7158607B2Promote regenerationMaximum functionX-ray/gamma-ray/particle-irradiation therapyIrradiation devicesX-rayInjury Site
Owner:WASHINGTON UNIV IN SAINT LOUIS +1
Multilayered microcultures
InactiveUS20060141617A1Accurate mimicFlexible and cost-effectiveBioreactor/fermenter combinationsCompound screeningBiological bodyCell adhesion
A multilayer microculture capable of modeling complex in vitro structures such as mammalian tissues and organ structures is provided, along with methods for producing such a microculture and methods of using such microcultures for assaying for modulators of cell-cell interaction, cell migration, cell proliferation, cell adhesion or cellular or organismal physiology. Further provided are methods of identifying hazardous materials such as environmental toxins and pollutants (e.g., carcinogenic compounds), and methods of monitoring organismal physiology.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Sustained DNA delivery from structural matrices
InactiveUS7427602B1Improve bioavailabilityPowder deliveryOrganic active ingredientsDna deliveryNucleic acid structure
Disclosed are particular 3-dimensional structural matrices containing nucleic acids, various fabrication processes and methods for the prolonged release of nucleic acids in various biological environments. The nucleic acid-matrix materials are created such that they maintain a defined space, allowing cellular migration, transfection and proliferation to occur in a controlled manner. The fabrication processes provide for both high incorporation efficiencies and control over the sustained nucleic acid release. The resultant nucleic acid-containing structural matrices are thus particularly useful in in vivo cell transfection and gene expression in the context of gene therapy.
Owner:RGT UNIV OF MICHIGAN
Methods and Therapeutic Compositions Comprising Plant Extracts for the Treatment of Cancer
A method of treating cancer by targeting two proteases, MMP-9 and cathepsin B is provided. Therapeutic compositions comprising one or more plant extracts that inhibit MMP-9 and / or cathepsin B, which are capable of inhibiting neoplastic and / or endothelial cell migration, tumour growth, tumour-induced angiogenesis and / or metastasis are also provided. The therapeutic compositions of the invention can be used in the treatment of cancer, and, methods of inhibiting tumour growth, tumour metastasis, and / or tumour-induced angiogenesis using the therapeutic compositions alone or in combination with an anti-cancer agent are, therefore, also provided.
Owner:BIOPHARMACOPAE DESIGN INT
Implantable materials having engineered surfaces and method of making same
Implantable materials having defined patterns of affinity regions for binding endothelial cells and providing for directed endothelial cell migration across the surface of the material. The affinity regions include photochemically altered regions of a material surface and physical members patterned on the material surface that exhibit a greater affinity for endothelial cell binding and migration than the remaining regions of the material surface.
Owner:VACTRONIX SCI LLC
Ocular solutions
InactiveUS7083803B2Reduce inflammationReduce bacterial growthBiocideSenses disorderDiseaseEverolimus
Owner:PEYMAN GHOLAM A DR
Ocular solutions
InactiveUS20050063996A1Reduce turbidityReduce inflammationAntibacterial agentsBiocideEverolimusCell migration
Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.
Owner:PEYMAN GHOLAM A DR
Use of integrin antagonists to inhibit angiogenesis
InactiveUS7074408B2Inhibit biological activityInhibit cell migrationAntibacterial agentsSenses disorderDiseaseIntegrin antagonist
The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
Owner:IMMUNEX CORP
Cell migration inhibiting compositions and methods and compositions for treating cancer
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
Owner:AVOLIX PHARMA
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
Owner:GENREMEDY
Ocular solutions
InactiveUS20060228394A1Reduce inflammationReduce bacterial growthAntibacterial agentsBiocideEverolimusOcular structure
Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.
Owner:MINU
Multiplexed assays of cell migration
InactiveUS20050009113A1Bioreactor/fermenter combinationsMaterial nanotechnologyCell migrationCell biology
Owner:MILLIPORE CORP +1
Ocular solutions
InactiveUS7087237B2Reduce inflammationReduce bacterial growthAntibacterial agentsBiocideEverolimusMacrolide resistance
Owner:PEYMAN GHOLAM A DR
Flowable hydrogels for control of cell in-migration
ActiveUS20120071865A1Minimize discomfortMinimize complicationPowder deliverySenses disorderOphthalmologyCell migration
Owner:INCEPT LLC
Inhibition of Tumour Cell Migration
The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
Owner:GW PHARMA LTD
Methods and systems for treatment of spinal disorders using trans-spinal direct current stimulation
ActiveUS20160243353A1Increase the number ofPromote differentiationExternal electrodesArtificial respirationDiseaseMedicine
Methods, systems and devices are disclosed for treating a spinal disorder by applying a source of direct current to a spinal cord in animals, including humans. Trans-spinal direct current stimulation (tsDCS) uses direct current via cathodal and / or anodal stimulation to induce cell proliferation, cell differentiation, and / or cell migration at or near the area of the spinal cord being treated, and up-regulates or down-regulates protein expression by cells at or near the area of the spinal cord being treated.
Owner:RES FOUND THE CITY UNIV OF NEW YORK
Automatic Cell Migration and Proliferation Analysis
The disclosed methods and apparatus provide for the automatic segmentation and analysis of the overall migration rate and proliferation rate of cells that may be used with any resolution image and without the need to prepare the sample or the image before the image is analyzed. In particular embodiments, the method or apparatus of analyzing a cell image comprise performing a structure tensor analysis and / or regularization and / or a histogram-based analysis and / or a level-set analysis to classify pixels in the image into a region of interest (ROI), corresponding to cell clusters, and a non-significant region. Methods and apparatus for cell migration analysis comprise means for computing the areas of the segmented ROIs for a set of images. Methods and apparatus for cell proliferation analysis comprise means for counting the number of cells within the segmented ROIs for a set of images.
Owner:KARAM LINA JAMIL +1
Plant extracts for treatment of angiogenesis and metastasis
InactiveUS20060228426A1Slow down and inhibit and prevent angiogenesisSlow down and inhibit and prevent metastasisBiocidePeptide/protein ingredientsLymphatic SpreadAngiogenesis growth factor
Extracts from plant material, or semi-purified / purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus, the use of the extracts to slow down, inhibit or prevent abnormal cell migration in an animal is also provided. Methods of selecting and preparing the plant extracts and methods of screening the extracts to determine their ability to modulate one or more cellular activity are described. The purification or semi-purification of one or more molecules from the described extracts is also contemplated as well as the use of these molecules, alone or in combination with an extract, to slow down, inhibit or prevent abnormal cell migration in an animal.
Owner:BIOPHARMACOPAE DESIGN INT
Tissue engineering bracket material capable of physically embedding active substances and preparation method thereof
The invention relates to a tissue engineering bracket material capable of physically embedding active substances and a preparation method thereof. The tissue engineering bracket material capable of physically embedding the active substances is prepared from 100 weight parts of biodegradable macromolecular substance and 0 to 20 weight parts of active substances, wherein the weight part of the active substances is not equal to zero; 100 weight parts of biodegradable macromolecular substance consists of 50 to 100 weight parts of synthetic macromolecular substance and 0 to 50 weight parts of natural macromolecular substance; the macromolecular substances and the active substances form a micromolecular nanofiber membrane or a composite macromolecular nanofiber membrane; and the active substances are bonded on the surface of the fiber membrane uniformly. The tissue engineering bracket material capable of physically embedding the active substances has high biocompatibility and sufficient mechanical strength, can be biodegraded, is suitable for proliferation and directed differentiation of stem cells, and has the functions of promoting cell migration adhesion and capturing the stem cells so as to induce regeneration of tissues such as bones, cartilages, nerves, skin and the like.
Owner:汪泱
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
InactiveUS7060271B2Peptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHuman typeReceptor activation
The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
Owner:MILLENNIUM PHARMA INC
Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents
InactiveUS20070117849A1Prevent and mitigate and even reverse developmentEasy to prepareBiocideDigestive systemIntestinal structureCTGF
This invention relates to inhibition of αv integrins, especially αvβ3 and αvβ6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells / myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis / cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.
Owner:MERCK PATENT GMBH
gRNA target sequences for endogenous overexpression of 1ncRNA-XIST and application thereof
ActiveCN107513531AImprove efficiencyFermentationVector-based foreign material introductionFetal growthCell migration
The invention discloses gRNA target sequences for endogenous overexpression of 1ncRNA-XIST, a CRISPR / dCas9 lentivirus system and application thereof. The gRNA target sequences are respectively as shown in SED ID No. 1, SED ID No. 2 and SED ID No. 3. The CRISPR / dCas9 lentivirus system comprises the gRNA target sequences for endogenous overexpression of 1ncRNA-XIST. A method for screening stable strains according to the characteristics that lentivirus must be integrated into a host genome is cooperated with CRISPR / dCas9 to realize the endogenous overexpression of the large fragment gene 1ncRNA-XIST, so that the defect of incapability of stably expressing the large fragment gene 1ncRNA-XIST in a traditional method is overcome, the efficient overexpression stable cell strain of the large fragment gene 1ncRNA-XIST can be obtained in a short time, or cells obtained by screening can stably express target genes, thereby obtaining stably silenced 1ncRNA-XIST downstream specific gene cell strain. The gRNA target sequences and the CRISPR / dCas9 lentivirus system have important guiding significance on the research of the function of 1ncRNA-XIST in the trophocyte migration and the effect of 1ncRNA-XIST in the proliferation disorder and fetal growth restriction process.
Owner:WUXI MATERNAL & CHILD HEALTH HOSPITAL
Cell migration inhibiting compositions and methods and compositions for treating cancer
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
Owner:AVOLIX PHARMA
Anti-angiogenesis effects of morinda citrifolia
InactiveUS20040086583A1Inhibit angiogenesisPrevent further growthBiocideUnknown materialsAnti-Angiogenesis EffectFruit juice
The present invention features a method of inducing an anti-angiogenesis effect within a tumorous region in the body of a mammal, wherein the method comprises the steps of administering, to a patient, a formulation comprising processed Morinda Citrifolia, wherein the processed Morinda citrifolia blocks formation of new blood vessels within a tumorous region by inhibiting tubule elongation and endothelial cell migration. Blocking the growth factors of said endothelial cells within said tumorous region inhibits tubule elongation and endothelial cell migration. In a preferred embodiment, the processed Morinda citrifolia comprises fruit juice and puree juice in various concentrations.
Owner:TAHITIAN NONI INT INC
Artificial silk fibroin nano-fiber nerve repair conduit and preparation method thereof
InactiveCN101579246APlay a role in guiding nerve regenerationPrevent collapseSurgeryCatheterFiberMedicine
The invention discloses a nerve repair conduit and a preparation method thereof. The nerve repair conduit consists of an inner layer conduit and an outer layer fiber wall, wherein the inner layer conduit consists of silk fibroin fibers arranged in the extending direction of the conduit, the outer layer fiber wall consists of the silk fibroin fibers encircling the conduit vertically and arranged axially, and the diameters of the silk fibroin fibers are between 50 and 3,000 nanometers; and the method for preparing the nerve repair conduit comprises the following steps: (1) preparing a regenerative silk fibroin film; (2) dissolving a pure regenerative silk fibroin film and preparing the silk fibroin fibers by using electrostatic spinning; and (3) collecting the silk fibroin fibers by using a roller device to obtain the nerve repair conduit. The nerve repair conduit is made from high-purity silk fibroin and is biodegradable, and the inner layer is made from parallel fibers arranged in the extending direction of the conduit and can conduct nerve cell migration; and the outer layer fibers are arranged by encircling the conduit axially and can support the conduit to prevent collapse.
Owner:SUZHOU UNIV
Receptor-type kinase modulators and methods of use
ActiveUS20060069077A1Strong specificityEliminate side effectsBiocideSenses disorderKinase activityTyrosine
The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and / or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.
Owner:SYMPHONY EVOLUTION
Microfluidic chip and method for studying non-contact type cell co-cultivation by using the same
InactiveCN102021116AReduce dosageImprove microenvironmentMicrobiological testing/measurementTissue/virus culture apparatusTransdifferentiationContact type
The present invention provides a microfluidic chip and a method for studying non-contact type cell co-cultivation by using the same. The microfluidic chip comprises a sample inlet, a cell cultivation room, a cell migration region and a waste pool. The upper end of the cell cultivation room is connected to the sample inlet and the lower end of the cell cultivation room is connected to the waste pool. Three parallel cell cultivation rooms are joined by cell migration region. The microfluidic chip provides good microenvironment for non-contact type cell co-cultivation, enables to form a concentration gradient in the cell migration region and facilitates observation of cell migration process in real time and research of transdifferentiation. The invention is advantageous in easy operation, simple manufacturing and small dosage of samples.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com